Your browser doesn't support javascript.
loading
Problematic severe asthma in children treated at high altitude: tapering the dose while improving control.
van de Griendt, Erik-Jonas; Verkleij, Marieke; Douwes, J Menno; van Aalderen, Wim M C; Geenen, Rinie.
Afiliación
  • van de Griendt EJ; Department of Pediatric Respiratory Medicine and Allergy, Emma Children's Hospital, Academic Medical Center , Amsterdam , The Netherlands .
J Asthma ; 51(3): 315-9, 2014 Apr.
Article en En | MEDLINE | ID: mdl-24304045
BACKGROUND: Multidisciplinary treatment at high altitude is a possible treatment option for problematic severe asthma (PSA) in children. This management can result in the tapering of inhaled corticosteroids. AIM: Our aim was to analyze the effect of multidisciplinary treatment at high altitude, notably the ability to taper corticosteroids. To get an insight into possible factors influencing tapering, we examined whether demographic variables, disease control and quality of life at treatment entrance could predict the tapering of corticosteroids. METHODS: This prospective open-phase cohort study analyzed the data of 43 children aged 8-17 years referred to a specialized high altitude treatment centre. Lung function (FEV1, FEV1/VC), inflammation (FeNO), medication level, asthma control (ACT) and quality of life [PAQLQ(S)] were evaluated on admission and at discharge. RESULTS: Thirty-two (74%) children fulfilled PSA criteria. Three (7%) children used daily oral steroids. After 72 ± 30 (mean ± SD) days of treatment, the mean dosage of inhaled corticosteroids (ICS) could be significantly reduced from 1315 µg ± 666 budesonide equivalent to 1132 µg ± 514. Oral steroid maintenance therapy could be stopped in all patients. FeNO, asthma control and quality of life improved (p < 0.001) from admission to discharge; FEV1 was in the normal range on both occasions. Apart from ICS levels at entrance, multiple regression analyses did not show any associated factor predicting the reduction of ICS dosage during treatment. CONCLUSION: The results indicate that high altitude treatment may be a treatment option for children with PSA, but it is not possible to predict ICS tapering off from health status variables at treatment entrance.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Antiasmáticos / Budesonida / Altitud Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Asthma Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Antiasmáticos / Budesonida / Altitud Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Asthma Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido